Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;53(12):3055-64.
doi: 10.1007/s10620-008-0294-y. Epub 2008 May 30.

Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells

Jorge-Shmuel Delgado  1 , Reba Mustafi, Jason Yee, Sonia Cerda, Anusara Chumsangsri, Urszula Dougherty, Lev Lichtenstein, Alessandro Fichera, Marc Bissonnette
Affiliations

Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells

Jorge-Shmuel Delgado et al. Dig Dis Sci. 2008 Dec.

Abstract

Background and purpose: Current therapies offer scant benefit to patients with advanced esophageal adenocarcinoma. We investigated the effects of Sorafenib, a multifunctional kinase inhibitor, on several growth regulatory pathways that control cell growth and survival in SEG-1 cells derived from Barrett's adenocarcinoma.

Methods: SEG-1 cells were exposed to acidified medium or taurocholic acid, with and without pre-incubation with Sorafenib. Cyclin D1 and E, c-Myc, and Bcl-2 expression levels as well as STAT3 activations were determined by Western blotting. Cyclin D1 mRNA was measured by real-time PCR. Apoptosis was assessed by TUNEL assay.

Results: Sorafenib significantly inhibited SEG-1 cell proliferation stimulated by acid or bile acid treatments and reduced cell survival. This drug significantly reduced the up-regulations of cyclin D1, cyclin E, c-Myc, and Bcl-2 as well as the activation of STAT3 in SEG-1 cells.

Conclusions: These results support a rational basis for future clinical studies to assess the therapeutic benefit of Sorafenib in esophageal adenocarcinoma.

PubMed Disclaimer

References

    1. Aliment Pharmacol Ther. 2007 Feb 15;25(4):447-53 - PubMed
    1. Gut. 1991 Dec;32(12):1441-6 - PubMed
    1. Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G335-42 - PubMed
    1. Anal Biochem. 2000 Oct 15;285(2):194-204 - PubMed
    1. J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 - PubMed

Publication types

MeSH terms